Your browser is no longer supported. Please, upgrade your browser.
Settings
KALV KalVista Pharmaceuticals, Inc. daily Stock Chart
KALV [NASD]
KalVista Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.98 Insider Own2.90% Shs Outstand18.50M Perf Week-2.59%
Market Cap521.70M Forward P/E- EPS next Y-2.11 Insider Trans-67.47% Shs Float15.43M Perf Month35.51%
Income-12.90M PEG- EPS next Q-0.43 Inst Own82.30% Short Float2.65% Perf Quarter53.01%
Sales18.00M P/S28.98 EPS this Y61.80% Inst Trans4.75% Short Ratio4.10 Perf Half Y73.43%
Book/sh6.04 P/B4.67 EPS next Y-37.90% ROA-13.70% Target Price30.40 Perf Year173.79%
Cash/sh6.01 P/C4.70 EPS next 5Y- ROE-19.60% 52W Range7.73 - 34.92 Perf YTD42.78%
Dividend- P/FCF- EPS past 5Y5.10% ROI-67.80% 52W High-19.24% Beta2.46
Dividend %- Quick Ratio6.60 Sales past 5Y40.40% Gross Margin- 52W Low264.81% ATR2.17
Employees14 Current Ratio6.60 Sales Q/Q69.60% Oper. Margin- RSI (14)63.80 Volatility8.48% 8.63%
OptionableNo Debt/Eq0.00 EPS Q/Q52.70% Profit Margin-71.80% Rel Volume0.74 Prev Close28.09
ShortableYes LT Debt/Eq0.00 EarningsMar 15 Payout- Avg Volume99.87K Price28.20
Recom- SMA2015.61% SMA5034.15% SMA20064.60% Volume73,863 Change0.39%
Mar-20-19Initiated Needham Buy $35
Oct-30-18Initiated Jefferies Buy $30
Sep-21-18Initiated Cantor Fitzgerald Overweight
Aug-31-17Initiated BTIG Research Buy $18
Mar-14-19 01:07PM  Is KalVista Pharmaceuticalss (NASDAQ:KALV) 147% Share Price Increase Well Justified? Simply Wall St. +18.57%
07:30AM  KalVista Pharmaceuticals Reports Fiscal Third Quarter Results Business Wire
Mar-13-19 08:41AM  Will KalVista Pharmaceuticals Continue to Surge Higher? Zacks +9.84%
Mar-11-19 09:57AM  Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings Zacks
09:55AM  Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing? Zacks
Mar-07-19 08:18AM  Top Ranked Momentum Stocks to Buy for March 7th Zacks
Feb-25-19 07:30AM  KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 Business Wire +8.15%
Feb-01-19 07:30AM  KalVista Pharmaceuticals Appoints Brian J. G. Pereira, MD to Board of Directors Business Wire
Jan-25-19 07:50AM  Research Report Identifies TechnipFMC plc, Glu Mobile, EPR Properties, Apartment Investment and Management, KalVista Pharmaceuticals, and DXP Enterprises with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +6.97%
Jan-04-19 07:30AM  KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans Business Wire
Dec-23-18 10:25PM  Hedge Funds Are Crazy About KalVista Pharmaceuticals, Inc. (KALV) Insider Monkey
Dec-14-18 07:30AM  KalVista Pharmaceuticals Reports Fiscal Second Quarter Results Business Wire
Dec-06-18 10:30AM  KalVista Pharmaceuticals (KALV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Nov-12-18 07:30AM  KalVista Pharmaceuticals Provides Clinical Update on KVD900 Business Wire
Nov-06-18 07:30AM  KalVista Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Oct-18-18 08:35AM  Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-25-18 07:30AM  KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference Business Wire
Sep-21-18 03:32PM  Cantor Fitzgerald's 7 Buys For 7 Biotechs Benzinga +20.67%
Sep-19-18 07:30AM  3 Biotech Stocks That Big Investors Are Snatching Up Barrons.com
Sep-14-18 07:30AM  KalVista Pharmaceuticals Reports Fiscal First Quarter Results Business Wire +10.42%
Sep-10-18 04:01PM  KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters Over-allotment Option to Purchase Additional Shares Business Wire
Sep-06-18 11:00AM  KalVista Pharmaceuticals (KALV) Q1 Earnings Preview: What to Look Out For Zacks
09:15AM  KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire
Sep-05-18 04:02PM  KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
Aug-27-18 07:45AM  Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +8.84%
Aug-07-18 07:30AM  KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference Business Wire +8.08%
06:32AM  Kalvebod Plc - Series 2 - Full Redemption GlobeNewswire
Jul-31-18 07:00AM  KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results Business Wire +10.50%
Jun-29-18 01:20AM  Kalvebod Plc - Series 2 Notice re Coll Redemption GlobeNewswire
Jun-25-18 07:35AM  Recent Analysis Shows Cigna, Basic Energy Services, KalVista Pharmaceuticals, QuinStreet, Armstrong World Industries, and NMI Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -5.57%
Jun-18-18 09:56AM  Kalvebod Plc - Series 2 Notice re Possible Redemption GlobeNewswire
May-31-18 07:30AM  KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference Business Wire
May-29-18 07:30AM  KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 Business Wire
May-16-18 07:30AM  KalVista Pharmaceuticals Recognizes HAE Day Business Wire
May-07-18 07:30AM  Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-02-18 07:30AM  KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting Business Wire -8.43%
Apr-18-18 07:30AM  KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting Business Wire
Apr-06-18 07:05AM  Wired News Sangamo Therapeutics Preclinical Study Data from MPS II in Vivo Genome Editing Program Published in Molecular Therapy ACCESSWIRE
Apr-03-18 09:49AM  Management Report GlobeNewswire
Mar-16-18 07:30AM  KalVista Pharmaceuticals Reports Fiscal Third Quarter Results Business Wire +9.22%
Mar-05-18 07:50AM  New Research Coverage Highlights KalVista Pharmaceuticals, Forestar Group, Unum Group, 22nd Century Group, Chevron, and The Michaels Companies Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
07:30AM  KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference Business Wire
Jan-05-18 07:30AM  KalVista Pharmaceuticals Commences Two Clinical Trials Business Wire -5.21%
Jan-01-18 11:42AM  ETFs with exposure to KalVista Pharmaceuticals, Inc. : January 1, 2018 Capital Cube
Dec-19-17 01:26PM  ETFs with exposure to KalVista Pharmaceuticals, Inc. : December 19, 2017 Capital Cube
Dec-18-17 11:25AM  KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q2, 2018 By the Numbers : December 18, 2017 Capital Cube -7.15%
Dec-14-17 07:30AM  KalVista Pharmaceuticals Reports Fiscal Second Quarter Results Business Wire -7.81%
Nov-08-17 07:30AM  KalVista Pharmaceuticals to Present at Stifel Healthcare Conference Business Wire
Nov-01-17 08:00AM  Investor Expectations to Drive Momentum within VWR, The Michaels Companies, KalVista Pharmaceuticals, PACCAR, Jaguar Health, and CPI Card Group Discovering Underlying Factors of Influence GlobeNewswire -5.66%
Oct-21-17 09:56AM  KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check Simply Wall St.
Oct-17-17 08:05AM  KalVista, Notable Investment and Collaboration Agreement ACCESSWIRE
Oct-16-17 01:58PM  Merck takes stake in small Cambridge rare disease biotech, lifting shares American City Business Journals
Oct-11-17 11:44AM  ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017 Capital Cube
09:46AM  Company News For Oct 11, 2017 Zacks
08:10AM  Today's Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc. ACCESSWIRE
Oct-10-17 04:06PM  Small-Cap Biotech Rockets After Dow's Merck Buys 10% Stake Investor's Business Daily +38.64%
09:27AM  KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers TheStreet.com
09:00AM  KalVista Pharma Wins Big on Merck Collaboration 24/7 Wall St.
08:46AM  UPDATE: KalVista shares surge 111% on news of Merck ownership stake, collaboration MarketWatch
07:30AM  KalVista Pharmaceuticals Announces Collaboration with Merck Business Wire
Oct-03-17 06:36PM  Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason? Simply Wall St.
Sep-19-17 05:52PM  ETFs with exposure to KalVista Pharmaceuticals, Inc. : September 19, 2017 Capital Cube
Sep-18-17 02:15PM  KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017 Capital Cube
Sep-14-17 07:30AM  KalVista Pharmaceuticals Reports Fiscal First Quarter Results Business Wire -9.70%
Aug-08-17 07:30AM  KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-01-17 10:08AM  KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q4, 2017 By the Numbers : August 1, 2017 Capital Cube
Jul-27-17 04:01PM  KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results GlobeNewswire
Jun-01-17 07:30AM  KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference GlobeNewswire
May-15-17 07:30AM  KalVista Pharmaceuticals to Recognize HAE Day 2017 GlobeNewswire
May-12-17 10:00AM  KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Mar-27-17 11:50AM  KALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Mar-17-17 06:04AM  KALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
Mar-16-17 05:24PM  KALVISTA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Mar-09-17 07:30AM  KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical GlobeNewswire
Feb-15-17 08:40AM  KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6% Zacks
Jan-20-17 11:01PM  Johnson & Weaver, LLP Initiates Investigations of Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited and Inotek Pharmaceuticals Corp. PR Newswire
Jan-19-17 11:14AM  Pittsburgh Law Office of Alfred G. Yates Jr., PC Announces Investigation of Carbylan Therapeutics, Inc. (CBYL), currently known as KalVista Pharmaceuticals, Inc. (KALV) PR Newswire
Jan-09-17 01:34PM  ETFs with exposure to KalVista Pharmaceuticals, Inc. : January 9, 2017 Capital Cube
01:34PM  ETFs with exposure to KalVista Pharmaceuticals, Inc. : January 9, 2017
Dec-21-16 12:32PM  ETFs with exposure to KalVista Pharmaceuticals, Inc. : December 21, 2016
Dec-20-16 06:10AM  KALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
Nov-30-16 10:28AM  KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q3, 2016 By the Numbers : November 30, 2016 Capital Cube
10:28AM  KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q3, 2016 By the Numbers : November 30, 2016
Nov-29-16 07:30AM  KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer GlobeNewswire
Nov-26-16 01:04PM  KALVISTA PHARMACEUTICALS, INC. Financials
Nov-23-16 05:28PM  KALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisit
Nov-22-16 07:30AM  KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics GlobeNewswire
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SVLSF IV, LLC10% OwnerMar 18Sale26.70262,4707,007,94954,973Mar 20 04:13 PM
Venrock Healthcare Capital Par10% OwnerMar 18Sale28.75500,00014,375,0001,544,112Mar 20 04:08 PM
Crockett Thomas AndrewCEOMar 14Sale30.163,00090,484268,510Mar 15 08:03 PM
SVLSF IV, LLC10% OwnerMar 05Sale23.0432,332744,81662,219Mar 06 09:05 AM
SVLSF IV, LLC10% OwnerMar 04Sale22.9143,378993,66063,112Mar 06 09:05 AM
SVLSF IV, LLC10% OwnerFeb 21Sale20.60172,5433,554,38664,309Feb 21 02:35 PM
SVLSF IV, LLC10% OwnerFeb 20Sale20.0223,235465,06969,073Feb 21 02:35 PM
SVLSF IV, LLC10% OwnerFeb 19Sale20.7318,420381,89869,714Feb 21 02:35 PM
Yea ChristopherChief Development OfficerJan 25Option Exercise0.005,4532388,422Jan 29 06:53 PM
Yea ChristopherChief Development OfficerJan 25Sale17.065,45393,01582,969Jan 29 06:53 PM
Yea ChristopherChief Development OfficerJan 23Option Exercise0.00600383,569Jan 24 07:48 PM
Yea ChristopherChief Development OfficerJan 23Sale17.0160010,20582,969Jan 24 07:48 PM
Yea ChristopherChief Development OfficerJan 22Option Exercise0.001,302684,271Jan 24 07:48 PM
Yea ChristopherChief Development OfficerJan 22Sale17.001,30222,13982,969Jan 24 07:48 PM
Feener Edward P.Chief Scientific OfficerJan 16Sale19.554,00078,210104,034Jan 18 05:42 PM
Crockett Thomas AndrewCEOJan 14Sale19.3310,000193,328271,510Jan 16 06:25 PM
SVLSF IV, LLC10% OwnerJan 07Sale20.412,59953,05170,222Jan 07 05:12 PM
SVLSF IV, LLC10% OwnerJan 03Sale20.011,70034,02270,294Jan 07 05:12 PM
SVLSF IV, LLC10% OwnerJan 02Sale20.002004,00070,341Jan 02 07:10 PM
SVLSF IV, LLC10% OwnerDec 31Sale20.0025,418508,46270,347Jan 02 07:10 PM
SVLSF IV, LLC10% OwnerDec 28Sale20.033,73474,78171,049Jan 02 07:10 PM
SVLSF IV, LLC10% OwnerDec 19Sale20.022,13642,75871,152Dec 21 04:19 PM
ORONSKY ARNOLD LDirectorSep 10Buy17.0058,8241,000,008388,766Sep 12 07:16 PM
Cha AlbertDirectorSep 10Buy17.001,058,82418,000,0081,359,149Sep 12 07:11 PM